The efficacy and safety of omalizumab in refractory chronspontaneous urticaria: Real-life experience in Turkey

Introduction: This study used real-world data to evaluate the effectiveness and reliability of omalizumab in treating recalcitrant chronic spontaneous urticaria in Turkish patients. Methods: Study data were collected retrospectively from eight tertiary-care hospitals in Turkey. This study included 132 patients with chronic spontaneous urticaria that were resistant to H1 antihistamine treatment in a dose up to four times the licensed dose and were treated with 300 mg/month of omalizumab for 6 months. Results: The mean weekly urticarial activity score (UAS7) after omalizumab treatment improved significantly compared to the pretreatment score (p <0.001). Treatment response was detected primarily in the 1st and 2nd months after treatment. No significant association was observed between omalizumab’s treatment effectiveness and disease-related parameters or laboratory data. The mean dermatology life quality index was 23.12 ± 6.15 before treatment and decreased to 3.55 ± 3.60 6 months after treatment (p <0.001). No side effects were reported in 89.4% (118) of the patients. Conclusion: This study showed that UAS7 decreased significantly and quality of life improved in omalizumab-treated patients. Moreover, treatment effectiveness was mainly observed in the first 2 months after treatment. However, no association was observed between omalizumab treatment effectiveness and disease-related parameters or laboratory data

A case of mycosis fungoides-like lesions developing after levetiracetam therapy

Levetiracetam is a relatively new antiepileptic drug that has previously not been associated with severe dermatological side effects. We report the case of a 31-year-old male treated with levetiracetam for seizures who subsequently developed a mycosis fungoides-like drug reaction that resolved upon dosage reduction

Acroangiodermatitis in a below-knee amputation stump

WOS: 000292659600026PubMed: 21575039

Efficacy of Topical Sodium Sulfacetamide in the Treatment of Mild and Moderate Acne Vulgaris: A Randomized, Comparative Study

Aydogan, Kenan/0000-0002-0193-1128WOS: 000301968600009Background and Design: Clindamycin and erythromycin are the most widely used topical antibiotics in the treatment of mild to moderate acne vulgaris. The combination of topical antibiotics with benzoyl peroxide increases the efficacy of the treatment and reduces antibiotic resistance of Propionibacterium acnes. Sodium sulfacetamide is a sulfonamide antibiotic. Although it has been known for many years, it is not widely used in acne treatment. However, it has recently acquired currency again. In this study, we aimed to assess the efficacy of sodium sulfacetamide in the treatment of mild to moderate acne vulgaris and to compare with the other widely used topical antibiotics. Material and Method: In our comparative study, 60 patients with acne vulgaris were randomly assigned into 3 groups, wherein the 1st, 2nd, and 3rd groups were applied sodium sulfacetamide 10% lotion, clindamycin 1% lotion, and erythromycin 2% gel, respectively, twice daily for 12 weeks. Each group consisted of 20 subjects. The treatment was combined with benzoyl peroxide in all groups. The patients were assessed for noninflammatory (open and closed comedones) and inflammatory (papules and pustules) lesion counts at 4, 8, and 12 weeks and, adverse events were recorded. Results: There was no significant difference between the groups for age, sex and acne duration (p>0.05). Statistically significant decrease was obtained with all 3 treatment regimens at the end of the study (p0.05). Conclusion: In this study, topical sodium sulfacetamide was found to be as effective and safe as erythromycin and clindamycin when combined with benzoyl peroxide in the treatment of mild to moderate acne vulgaris. These results should be supported by studies with larger cohorts. (Turkderm 2012; 46: 33-8